References
- Price P A, Nashimoto S K. Radioimmunoassay for the vitamin-K-dependent protein of bone and its discovery in plasma. Proc Acad Sci Usa 1980; 77: 2234–2238
- Price P A, Parthermore J G, Deftos L J. New biochemical marker for bone metabolism. J Clin Invest 1980; 66: 878–881
- Gundberg C M, Lian J B, Gallop P M, Steinberg J J. Urinary g-carboxyglutamic acid and serum osteocalcin as bone markers; studies in osteoporosis and Paget's disease. J Clin Endocrinol Metab 1983; 57: 1221–1224
- Brown J P, Delmas P D, Malaval L, Edouard C, Chapuy M C, Meunier P J. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984; 1: 1091–1093
- Compston J E. Thyroid hormone therapy and the skeleton. Clin Endocrinol 1993; 39: 519–520
- Garnero P, Vassy V, Bertholin A, Riou J P, Delmas P D. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994; 78: 955–959
- Letizia C, Minisola S, Cerci S, Tarsitani P, De Ciocchis A, Scavo D. Serum activity of angiotensin converting enzyme and osteocalcin levels in hyperthyroidism. Minerva Endocrinol 1992; 173: 103–106
- Bergmann P, Dedister A, Demister MN, Decominck I, Corvilain J. Serum bone Gla-protein (BGP) in primary hypothyroidism before and during treatment with thyroid hormones. Horm Metab Res 1989; 21: 47–48
- Faber J, Perrild H, Joansen J S. Bone Gla-protein and sex hormone-binding globulin in nontoxic goiter: parameters for metabolic status at the tissue level. J Clin Endocrinol Metab 1990; 70: 49–53
- Faber J, Perrild H, Johansen J S. Serum bone Gla-protein (BGP) during treatment of hyperthyroidism and hypothyroidism. Horm Metab Res 1991; 23: 135–138
- Ross D S, Nerr R M, Ridgway B C, Daniels Gh. Subclinical hyperthyroidism and reduced bone density. Am J Med 1987; 82: 1167–1170
- Ross D S. Monitoring L-Thyroxine therapy: Lessons from the effects of L-thyroxine on bone density. Am J Med 1991; 91: 1–4
- Franklyn J A, Betteridge J, Daykin J, Holder R, Oates G D, Parle J V, Lilley J, Heath D A, Sheppard M C. Long-term thyroxine treatment and bone mineral density. Lancet 1992; 340: 9–13
- Grant D J, McMurdo ME T, Mole P A, Paterson C R, Davies R R. Suppressed T. S.H levels secondary to thyroxine replacement are not associated with osteoporosis. Clin Endocrinol 1993; 39: 529–533
- Lee M S, Kim S Y, Lee M C. Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J Clin Endocrinol Metab 1990; 70: 766–770
- Goretzki P E, Frilling A, Simon D, Rastegar M, Ohman C. Growth regulation of human thyrocytes by thyrotropin, cyclic adenosine monophosphate, epidermal growth factor and insulin-like growth factor. Growth Regulation of Thyroid Gland and Thyroid Tumors. Frontiers in Hormone Research, Basel 1989; pp. 56–60
- Studer H, Peter H J, Gerber H. Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular goiter growth. Endocr Rev 1989; 10: 125–135
- Paul T L, Kerrigan J, Kelly A M, Braverman L E, Baran D T. Long-term L-thyroxine is associated with decreased hip bone density in premenopausal women. JAMA 1988; 259: 3137–3141
- Taelman P, Kaufman J M, Janssens X, Vandecavter H, Vermeulen A. Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goiter treated with thyroid hormone. Clin Endocrinol 1990; 33: 107–117
- Toh S, Brown P H. Bone mineral content in hypothyroid male patients with hormone replacement: a 3 years study. J Bone Min Res 1990; 5: 463–467